07 Mar | 2025
The BBRC participates in the ReTain study to evaluate a new pharmacological therapy for preclinical Alzheimer's
New clinical trial ReTain
The Barcelonaβeta Brain Research Center (BBRC), research center of the Pasqual Maragall Foundation, has started the recruiting process for the ReTain clinical trial, from the pharmaceutical company Janssen-Cilag S.A., a multicenter study that evaluates the effectiveness, safety and immunogenicity of an active immunotherapy directed at phosphorylated tau, in participants with preclinical Alzheimer's.
ReTain, currently in the recruitment phase, joins the Ahead clinical trial, also underway at the BBRC.
